Although new agents are implemented to cancer therapy, we lack fundamental understandings of the mechanisms of chemoresistance, the main obstacle to cure in cancer. Here we review clinical evidence linking molecular defects to drug resistance across different tumour forms and discuss contemporary experimental evidence exploring these mechanisms. Although evidence, in general, is sparse and fragmentary, merging knowledge links drug resistance, and also sensitivity, to defects in functional pathways having a key role in cell growth arrest or death and DNA repair. As these pathways may act in concert, there is a need to explore multiple mechanisms in parallel. Taking advantage of massive parallel sequencing and other novel high-throughput technologies and base research on biological hypotheses, we now have the possibility to characterize functional defects related to these key pathways and to design a new generation of studies identifying the mechanisms controlling resistance to different treatment regimens in different tumour forms.
INTRODUCTION
Chemoresistance remains the main obstacle to cancer cure. Despite a titanic number of experimental studies, the number of clinical therapy studies focusing on the mechanisms of resistance is small and, in general, include a small number of patients each. Here we will review and discuss contemporary findings related to chemoresistance in vivo. Considering the individual mechanisms, their impact on drug sensitivity has been described for a limited number of drug regimens in few types of cancer only; the best examples being the impact of disturbances in homologous end repair on platinum and anthracycline compound sensitivity in breast and ovarian cancer, and the effects of TP53 mutations in breast cancer and haematological malignancies. As for experimental in vitro evidence, a comprehensive review of experimental research related to chemoresistance is beyond the scope of this paper. Instead, we include experimental evidence of relevance to the in vivo findings.
Although some factors, such as expression of the metalloproteinase TIMP-1, has been correlated with resistance to some combination regimens 1,2 and expression of the t-protein has been related to resistance to taxanes, 3 most of the gene cascades associated with chemoresistance identified relates to gene pathways involved in apoptosis/senescence and DNA repair. Considering factors like human epidermal growth factor receptor 2 (HER-2) and/or topoisomerase-II (Topo-II) amplifications, these parameters do not predict drug resistance; rather, they advocate a 'dose-dependent sensitivity' to anthracyclines. As for the growth factor/protein kinase pathways, such as the phosphatase and tensin homologue/phosphoinositide 3-kinase/mammalian target of rapamycin (PTEN/PI3K/mTOR) pathway, these factors have a role in resistance to endocrine therapy in breast cancer, but their role in resistance to chemotherapy remains to be addressed. Further, components of the PTEN/PI3K/mTOR pathway also influence p53 function and interacts with DNA repair mechanisms. In contrast, merging evidence links key pathways regulating apoptosis/senescence and DNA repair to chemoresistance. Notably, most cancer susceptibility genes are involved in these pathways as well. Thus, we will re-examine the previously proposed hypothesis that genes involved in hereditary cancer syndromes may act as 'beacons', identifying key mechanisms regulating drug resistance in vivo. 4 
MODELLING DRUG RESISTANCE IN VIVO, DEFINING PROGNOSTIC AND PREDICTIVE FACTORS
The issue of prognostic versus predictive factor have been reviewed by the authors in detail elsewhere; 5, 6 only a brief summary will be presented here. A prognostic factor may be any tumour characteristic associated with either relapse-free or overall survival subsequent to local treatment (surgery and/or radiotherapy) for a primary cancer (Figure 1a) . In contrast, a predictive factor is a parameter associated with response to a particular anti-tumour agent.
There are three general models for studying predictive factors. The first model ( Figure 1a ) takes advantage of adjuvant therapy trials. Examples of such studies are the seminal trials establishing the predictive role of the oestrogen receptor in anti-hormonal therapy, comparing receptor expression with outcome in patients randomized to either anti-oestrogen tamoxifen or no adjuvant therapy after primary surgery. 7 Currently, such trials may compare treatment with a less extensive ('regimen A') versus more extensive ('regimen A þ drug B') regimen.
The second model ( Figure 1b ) involves studying anti-tumour response by measuring alterations in tumour size in response to defined therapeutic regimens. 5 Although this model may be applied in metastatic disease, over the last two decades it has been more widely adopted in pre-surgical, or so-called 'neoadjuvant', treatment for primary cancers. Whereas tumours increasing in size on therapy contain a substantial amount of therapy-resistant cells, tumours obtaining a so-called 'complete pathological response' to chemotherapy contain cells sensitive to therapy. The fact that a complete pathological response in response to primary chemotherapy correlates to long-term survival in breast cancers 8 indicates complete pathological response to be associated with eradication of micrometastases as well.
A third possibility is to analyse repeated samples before and after therapy, and assess elimination versus enrichment of certain cell clones harbouring distinct defects. This may link specific gene mutations to chemosensitivity or resistance (Figure 1c ). Implementing massive parallel sequencing ('next generation sequencing') will greatly increase the feasibility of this strategy, as the percentage of sequence reads harbouring a mutation (thus, reflecting the percentage of mutated cells) from any sample can be easily calculated (Figure 2 ). Needless to say, prognostic as well as predictive factors are, by definition, statistical correlates; the fact that individual factors may be covariates warns for caution linking such factors to tumour biology.
TP53
No single gene has been more extensively studied than TP53, the gene coding for the p53 protein. Thus, the search item 'p53' provides478 000 hits in the ISI Web of knowledge database (January 2013), a figure 10-fold the numbers for HER-2 and erbB-2 combined, and nearly 20-fold the number for BRAF.
Germline TP53 mutations are associated with the classical LiFraumeni syndrome (LF) and the more lately defined 'LF-like' syndrome, the latter characterized by somewhat less stringent criteria. 9 Both syndromes are associated with enhanced risk of multiple malignant diseases at early age; the most characterized being different types of sarcomas. p53 contains a frequent arginine/proline polymorphism in codon 72. Although Arg72 has been shown to be more effective in inducing apoptosis compared with Pro72, 10 contemporary evidence from experimental studies do not indicate a significant effect of this variant on chemosensitivity, and a recent meta-analysis found no effect on cancer risk.
11
When evaluating TP53 mutation function in vivo, there is a need to emphasize on proper detection methods. Because of the fact that many p53 protein variants harbouring missense mutations are slowly degraded, causing a protein detectable by immunostaining, p53 staining is widely used as a surrogate marker for TP53 mutation status. However, we 12 and others 13 have shown that about 30% of TP53 mutations are not associated with immunostaining in breast cancers. Moreover, such lack-ofstaining relates, in particular, to truncating non-sense mutations that, in general, are associated with complete loss of protein function. For this reason, papers evaluating p53 status only by immunostaining are not examined in this review.
Although direct application of p53 through retroviral vectors have achieved tumour regression in lung cancers, 14 such trials were terminated due to poor systemic delivery. The first trials 15 exploring compounds that restore p53 function in tumours harbouring mutations that cause conformational changes of the p53 protein 16, 17 have been undertaken. Although this is an interesting approach, such strategies are unlikely to work in tumours harbouring non-sense TP53 mutations.
TP53 mutations have been associated with chemoresistance in different haematological malignancies such as chronic lymphocytic leukemia, T-cell leukemia, acute lymphoblastic leukemia, Burkitt's lymphoma and acute myeloid leukemia, as well as in aggressive B-cell lymphoma. The regimens to which TP53 mutations predicted drug resistance included treatment with purine (pentostatin) or pyrimidine (fludarabine) analogues, as well as combination regimens containing anthracycline, cyclophosphamide, cytosine arabinoside, vincristine and/or etoposide. [18] [19] [20] [21] [22] [23] Considering primary (pre-surgical) treatment of breast cancer, TP53 mutations have been associated with anthracycline and mitomycin resistance, 12, [24] [25] [26] but not with taxane resistance; 26, 27 similarly, one study evaluating efficacy of taxanes in the adjuvant setting 28 and two studies evaluating anthracyclines and taxanes administered in concert, or sequentially, found no effect of TP53 mutation status on response. 29, 30 Yet, there is evidence at variance. Thus, de The and colleagues 31 found TP53 mutations to predict improved response to chemotherapy in breast cancer; this effect, however, was observed among patients receiving cyclophosphamide at high doses in concert with anthracyclines. In a recent experimental study, Song et al. 32 provided interesting evidence potentially explaining this finding. N-methylpurine DNA glycosylase, known to be expressed in breast cancer, triggers DNA strand breaks in response to alkylating agents by increasing abasic sites. Although these lesions induced p53-dependent growth arrest and were effectively repaired in p53-proficient cells, they were repaired at poor efficiency in cells mutated for TP53, subsequently leading to cell death. Figure 2 . Theoretical example illustrating the potential use of massive parallel sequencing to identify factors (mutations) predicting chemoresistance. The frequency of a mutation (here G4A) within a biopsy may be assessed directly by massive parallel sequencing through calculations of the numbers of mutated versus non-mutated reads (these numbers must be corrected for copy number of the gene in question as well as percentage of non-tumour cells in the biopsy, but for clarity these corrections are not illustrated in the figure) . Comparison of these data between pre-and post-treatment samples may identify mutations that are enriched in the tumour through the course of treatment, and therefore likely to be associated with resistance to therapy.
Bonnefoi et al. 33 explored the predictive value of TP53 status in a group of 1856 patients randomized to primary medical treatment with either 5-fluorouracil, epirubicin and cyclophosphamide or combined treatment with docetaxel and epirubicin. TP53 mutations did not predict either direct therapy response or progression-free survival in any of the two arms. Of note, in this study, TP53 mutation status was assessed using a yeast assay, and the frequency of tumours classified as TP53-mutated (44%) exceeded the corresponding frequency usually detected in breast cancer (20-30%) . Importantly, a fraction of patients enroled in the '5-fluorouracil, epirubicin and cyclophosphamide' arm did not have a conventional regimen but received cyclophosphamide at high doses. Thus, the fact that most patients in this study received either taxotere or cyclophosphamide at high doses may have contributed significantly to the result.
Regarding other cancer forms, TP53 mutations was found to predict a better response to combined platinum-taxane therapy but not to platinum monotherapy in ovarian cancer patients. 34, 35 Interestingly, TP53 mutations have been found to be associated with resistance to cisplatin combined with etoposide 36 in nonsmall cell lung cancer as well as to cisplatin combined with ifosfamide. 37 The results from the former study 36 may be consistent with the observations regarding anthracyclines in as much as etoposide, being a Topo-II inhibitor, resembles the anthracyclines with respect to mechanism of action. Ifosfamide, on the contrary, is metabolized into cyclophosphamide in vivo. The findings from the second study may be inconsistent with the results from the study by de The and colleagues, 31 but notably the de The study applied cyclofosfamide as a 'high-dose' regimen of 1200 mg/m 2 every second week (contrasting a regular dose of cyclophosphamide 600 mg/m 2 every third week in breast cancer). Further, these results 37 may have been influenced by administration of cisplatin in concert.
Although p53 is involved in multiple cellular processes, including growth arrest, DNA damage repair, apoptosis, senescence 38 and, by more recent evidence, also necrosis and autophagy, 39, 40 we have no clear understanding of which process is responsible for tumour suppression or chemotoxic cell death. In addition to apoptosis, experimental evidence has favoured senescence as a p53-induced anti-tumour response, 41 whereas others, 42 using different models, reported p53-induced senescence to hamper DNA response by blocking apoptosis. Although this phenomenon occurred only in mutant tumours with concomitant loss of the normal p53 allele (loss of heterozygosity), notably loss of heterozygosity does in fact occur in most human breast cancers harbouring TP53 mutations. 12, 24 p53 is not primarily activated by transcriptional upregulation but by post-translational events, including phosphorylations, acetylations, sumoylations and monoubiquitinations. 38 Phosphorylation occurs at multiple sites; although experimental evidence indicate phosphorylations at serine 15 and 20 by the ataxia telangiectasia mutated (ATM) and chk2 kinases to have a critical role in response to DNA damage, phosphorylation at serine 46, which is caused by other kinases, seems of major importance in the execution of apoptosis. [43] [44] [45] The mechanisms deciding between growth arrest versus apoptosis is incompletely understood, but there seems to be structural differences in the promoters of genes responding rapidly (like the CDKN1A coding for p21) as compared with the more slowly acting genes involved in apoptosis, 46, 47 and integrated models for a time sequence involving protein phosphorylations and promoter activation has been proposed. 48 Drug doses may have influenced outcome as well; thus, multiple kinase inhibition by low doses of reversine were shown to induce apoptosis in a p53-dependent manner. In contrast, elevated doses caused abortive mitosis leading to mitotic catastrophy and apoptosis in p53-deficient cells. 49 In addition, some mutants reveal gain-of-function 50 and some mutants, such as codon 175 mutations, are involved in DNA binding, but induces conformational changes as well. 51 Finally, p53 may induce apoptosis in a non-transcriptional way through direct binding to components of the bcl-2 system, such as bax. 52 The fact that chemoresistance in vivo has been associated with TP53 mutations affecting the DNA-binding loop 2 (L2) and loop 3 (L3) domains do not exclude that transcription-independent apoptosis could have a critical role in drug response in as much as the L3 domain, in particular, has been linked to transcription-independent apoptosis in addition to DNA binding. 53 Notably, multiple TP53 splice variants have been discovered 54 and several of these have been shown to modulate full-length TP53 transcription in vitro. Although the biological effects of the splice variants in vivo remains to be fully elucidated, interestingly, expression of an isoform lacking codon 257-322 did not affect metastatic propensity neither in wild-type tumours nor in tumours harbouring TP53 mutations; 55 in contrast, p53g, lacking part of the C-domain, was shown to neutralize the negative prognostic effect of TP53 mutations. 56 Thus, it should be of interest to learn whether this variant (and potentially, others), may influence chemosensitivity as well.
Interestingly, recent experimental evidence in mice has questioned whether the mechanisms of tumour suppression and tumour DNA damage response may differ. Thus, Li et al. 57 and Brady et al. 58 reported tumour suppression with TP53 mutants defective in causing cell cycle arrest, apoptosis, as well as senescence in response to DNA damage. Regarding chemoresistance in vivo, the predictive value of somatic TP53 mutations with respect to anthracycline/mitomycin resistance does not seem to differ between TP53 mutations exclusively observed as somatic and those mutations that have been detected as germline mutations in LF/LF-like families as well (Table 1) .
OTHER GENES INVOLVED IN THE P53 PATHWAY
ATM phosphorylates p53 at serine 15 and chk2 at threonine 68 in response to DNA damage. Subsequently, chk2 phosphorylates p53 at serine 20, preventing MDM2 protein binding. Although chk2 also phosphorylates p53 at six additional sites, including serine 313 and 314 located in the nuclear localization signal, 38 the role of these phosphorylations in p53 activation remains poorly understood. The ATM/chk2 pathway is considered a major mechanism of p53 activation in response to DNA damage, 59 although some reports suggest ATM as well as chk2 to be redundant to this function. [60] [61] [62] Although evidence linking heterozygous ATM mutations to breast cancer risk is at variance, 63 a moderately elevated risk has been associated with heterozygous mutations located in certain protein domains. 64 Ataxia telangiectasia, however, is a recessive disorder; thus, individuals carrying biallelic ATM mutations in addition are at significant elevated risk of multiple cancer forms. 65 Interestingly, recent evidence indicate cancer risk to be particularly elevated among individuals carrying 'null' mutations, that is, mutations associated with lack of ATM protein expression, 66 an interesting parallel to our finding that low ATM expression levels, but not heterozygous mutations, 67 was associated with drug resistance (see details below).
Following an initial report of a CHEK2 germline mutation in a family diagnosed with the LF syndrome, 68 subsequent studies detected a BRCA2 mutation in the same family, and BRCA2 mutations are now considered the cause of several cases of LF/LF-like families. 69 However, truncating (but not missense) CHEK2 mutations, the most common being the del1100C variant detected in 0.5-1% of north-eastern Europeans, are associated with a 2-to 3-fold elevated risk of breast cancer, 70, 71 as well as other tumour forms, such as cancers of the thyroid and prostate.
Although several studies correlated TP53 mutations to therapy failure in breast cancer, the same studies 12, 24, 25 reported tumours failing on therapy harbouring wild-type TP53 and tumours responding to treatment despite harbouring TP53 mutations known to impair p53 protein function (Table 1) . One explanation as to why tumours harbouring wild-type TP53 are resistant to therapy could be defects involving other components of the 'p53 pathway'. Thus, we examined whether defects in Chk2 or ATM, the main upstream activators of p53 in response to genotoxic damage, may substitute for TP53 mutations, rendering tumour cells resistant to chemotherapy. Indeed, although rare, we found non-sense mutations in the CHEK2 gene may substitute for TP53 mutations causing anthracycline resistance in primary breast cancers. 25, 72 These mutations caused early stop codons with complete loss of protein expression. In contrast, tumours harbouring CHEK2 missense mutations, including I157T, shown to infer a marginal elevated risk of breast cancer, 71 seemed to respond normally to therapy. Among tumours resistant to anthracyclines lacking mutations in either TP53 or CHEK2, we found low ATM expression levels (but not ATM mutations) to predict anthracycline/mitomycin resistance. 67 These findings link ATM and chk2 to p53 activation in response to DNA damage in breast cancer, and may be of significant importance to our understanding of tumour biology and therapy as well.
Regarding p53's downstream targets, these genes are seemingly organized in multiple redundant pathways, 73, 74 and inactivating mutations are likely to be compensated for when tumour cells are exposed to cytotoxic stress. In addition, some of p53's downstream targets, such as CDKN1A (coding for p21), have a very low mutation frequency in cancers, making assessment of their impact on therapy response challenging. 75, 76 However, Zenz et al. 77 found expression of miR-34a, a p53-inducible micro-RNA, to predict resistance to fludarabine in chronic lymphatic leukemias independent of TP53 and 17p deletion status.
TP53 ANALOGUES TP63 AND TP73
In mouse models, loss of p63 function causes skin and limb defects with neonatal death; in contrast, loss of p73 function not only causes neurological defects but an increased cancer risk as well. 78 Although TP63 germline mutations cause multiple limb and skin defects in humans, 79 to the best of our knowledge germline mutations in TP73 have not been detected.
The evolutionary conserved TP53 homologues TP63 and TP73 express different splice variants, some of which execute functions resembling wild-type p53 with respect to, for example, G1 cell cycle arrest and apoptosis (for details see refs 78, 80) . The issue is complicated by the fact that different isoforms, like Tap73 and DNp73, act like antagonists to each other; the former being proapoptotic and the latter being anti-apoptotic. 81 Experimental evidence has linked p73 in particular, but also p63 to tumour suppression as well as to DNA damage response. [81] [82] [83] [84] Both p63 and p73 isoforms have been linked to resistance to cisplatinum in ovarian as well as triple-negative breast cancer cells lines. 85, 86 Data from human studies are few, but one study found high expression of the p73-dominant negative isoforms (DNp73 and DN'p73) to be associated with platinum resistance in ovarian cancers harbouring TP53 mutations.
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MDM2 AND MDM4 Although MDM2 and MDM4 execute their oncogenic effects by overexpression, the importance of each protein and lack of redundancy are illustrated by the fact that MDM2 and MDMX (the mouse homologue of MDM4) deletion in mice cause embryonic lethality, the former at the blastula stage and the latter 7-11 days into the gestation period. 88 No germline mutations inactivating MDM2 has been reported in humans (probably because these would, such as in mice, be lethal at an early embryonic stage). However, interestingly, two promoter single-nucleotide polymorphisms (SNPs) influencing C493T  Q165X  PR  A503C  H168P  SD  G527T  C176F  SD  C569T  P190L  SD  A578T  H193L  PR  T581G  L194R  PR  T584C  I195T  PD, PR  G610T  E204X  PD  T613G  Y205D  SD  G711T  M237I  PR  A745G  R249G  PD  A763T  I255F  PR  G818C  R273P  SD  G973T  G325X  PD  G1010T R337L PR (c) Association between TP53 mutations (L2/L3) and response to chemotherapy. Pooled data from (9, 21, 22; total n ¼ 176;
TP53-mutated 15 25 TP53 wild-type 13 123 Abbreviations: LF, Li-Fraumeni; LFL, LF-like; PD, progressive disease; PR, partial response; SD, stable disease; CR, complete response.
a Note that several of the missense mutations associated with chemoresistance (PD) have also been detected as germline mutations in families diagnosed with the LF or the LFL syndrome.
MDM2 expression levels have been associated with cancer risk. [89] [90] [91] These SNPs are located in the so-called promoter P2, activated by factors like p53 in response to genotoxic stress. 92 A second promoter, P1, regulates MDM2 levels under 'non-stressed' conditions, and PTEN is a major ligand suppressing basal MDM2 expression levels. 93 Although Gajjer et al. 94 found MDM2 to suppress p53 protein levels under non-stressed conditions, following ATM-dependent phosphorylation of MDM2 at serine 395, the MDM2 protein became a stabilizer of p53 mRNA in response to stress. The potential impact of these findings yet remains to be settled. Although intronic SNPs in the MDM4 gene have been related to cancer risk, 95 
MDM2 binds and ubiquitinates p53, thereby targeting it for degradation. In addition, MDM2 binds to and inhibits the retinoblastoma (RB) protein, 96 causing the release of E2F1, which it further activates through direct binding. 97 Notably, MDM2 inhibition has been shown to induce apoptosis through the E2F1-p73 pathway in p53-deficient cells. 98 Somatic MDM2 amplification has been considered an alternative mechanism of p53 inactivation, and is commonly recorded in soft tissue and osteosarcomas and gliomas, less frequently in melanomas and colon cancer. [99] [100] [101] [102] Amplifications of MDM4 has been reported albeit at low incidence in breast cancers and gliomas, 102, 103 and in retinoblastomas (RBs), for which experimental evidence indicates a role in tumour progression. 104 Interestingly, MDM4 overexpression has been associated with lack of response to the MDM2 antagonist nutlin in chronic lymphoma cells in vitro. 105 In a recent phase I study exploring an MDM2 antagonist administered as monotherapy to patients with liposarcomas, for which most were amplified for MDM2, one patient achieved a partial tumour response while several had stable disease, 106 advocating further studies in concert with chemotherapy.
THE RB-E2F1 PATHWAY Germline mutations affecting the RB1 gene cause RBs in young children. Now, with improved therapy and better survival for their RBs it has become clear that these individuals have an increased risk of other cancers later in life as well. 107 Somatic alterations of RB1, including large deletions and promoter methylations, have been detected in different cancer forms, including breast cancer (see references in Berge et al. 108 ). In a recent paper, Witkiewicz et al. 109 found an RB-deficiency gene expression signature to be associated with increased chance of a pathological complete response among breast cancer patients receiving primary chemotherapy with 5-fluorouracil, adriamycin and cyclophosphamide, but also patients treated with combined anthracycline-and taxane-containing regimens. In contrast, we found RB1 point mutations and intragenic deletions, albeit rare, to be associated with lack of response to anthracyclines and mitomycin in primary as well as metastatic breast cancers. 108, 110 Interestingly, these mutations were located in the protein pocket domain and have never been reported as germline mutations in RB families (Table 2) .
Experimental evidence have revealed the RB protein to have an important role in execution of cell cycle arrest and cell senescence. [111] [112] [113] Although a pro-apoptotic function has been reported, 114, 115 many studies have found loss of RB function to enhance apoptosis due to inappropriate S-phase control, [116] [117] [118] causing increased sensitivity to taxanes as well as platinum compounds in different cell lines. 119, 120 In contrast, p53-induced apoptosis in response to doxorubicin and combined treatment with metotrexat and 5-fluorouracil has been found to be blunted following RB knockdown in different cell lines. 121 Interestingly, Schmitt et al. 41 reported the p53 and the p16/RB pathway to act in concert, inducing senescence and leading to tumour regression in response to cyclophosphamide treatment in a murine model. Notably, others 122 reported senescence to occur in response to doxorubicin at low doses, whereas higher doses caused quiescence in cell cultures.
The cross talk between the RB and p53 pathway is complicated. In addition to MDM2's role as a regulator of both p53 and pRB function described above, ATM and chk2 has been shown to activate E2F1 by phosphorylations, 123, 124 and E2F1 has been reported to activate pro-apoptotic genes, including TP73, as well as to activate ATM, causing phosphorylation of chk2 and p53 in response to DNA damage. 125, 126 Further, p21, regulating pRB function through inhibition/induction of cyclin/cdk complexes, 127 is a direct target for transcriptional activation by p53 (Figure 3 ).
HER-2 AMPLIFICATION AND CHEMORESISTANCE
HER-2 amplification is associated with a poor prognosis in primary breast cancers not receiving adjuvant therapy. 128, 129 Although treatment with trastuzumab dramatically improves relapse-free survival in the adjuvant setting, 130 the percentage of patients with HER-2-amplified tumours that relapsed following adjuvant chemotherapy with trastuzumab resembles the relapse rate among patients with non-amplified tumours. Similar to nonamplified tumours, HER-2-amplified tumours are subject to therapy failure with respect to chemotherapy as well as endocrine treatment; 8 thus, the same mechanisms causing resistance in HER-2 non-amplified tumours are likely to operate in the amplified tumours as well. In addition, failure on trastuzumab may relate to HER-2-specific mechanisms; thus, treatment with the HER-2 thyrosine kinase inhibitor lapatinib and trastuzumab in concert were found to be more effective as compared with lapatinib monotherapy in patients failing trastuzumab treatment, 131 and adding pertuzumab, an antibody specifically blocking HER-2/HER-3 dimerization, improved treatment with trastuzumab and chemotherapy. 132 HER-2 amplification has been associated with anthracycline sensitivity. Thus, HER-2-positive breast cancers gain an additional benefit from anthracycline-containing chemotherapy, but require higher doses compared with non-amplified tumours. [133] [134] [135] [136] Yet, it is not clear whether this effect is due to HER-2 overexpression as such, or due to co-amplification of Topo-II. The TOPO-II gene is located close to HER-2 on chromosome 17q, and is co-amplified in about 40% of HER-2-amplified breast cancers. 137 Topo-II is a major target for anthracycline compounds, and several studies have reported TOPO-II amplification to be a better predictor of anthracycline sensitivity compared with HER-2 amplifications. [138] [139] [140] Although experimental evidence do not suggest HER-2 overexpression to cause drug resistance, 141 interestingly, one study 142 found HER-2 overexpression to be associated with improved response when adding a taxane to anthracycline-containing chemotherapy in breast cancer patients. Finally, HER-2 activates the PI3K/akt/mTOR pathway, discussed in detail below. In conclusion, these data indicate we are dealing with a 'response sensitizer' and not a mechanism of resistance blocking the effect of chemotherapy.
ACTIVATING MUTATIONS IN THE PTEN/PI3K/MTOR PATHWAY AS A CAUSE OF THERAPY RESISTANCE
The PTEN/PI3K/mTOR pathway has recently been reviewed in detail by Baselga. 143 Germline mutations in the PTEN gene cause the Bannayan-Riley-Ruvalcaba syndrome or the Cowden syndrome. Although they both cause hamartomas and several other characteristics, individuals carrying the Cowden syndrome are also prone to elevated cancer risk, in particular cancers of the thyroid and breast. 144 While germline mutations in PIK3CA and AKT3 (the Akt isoform expressed in neural tissue) may cause megalencephaly, 145 a most recent study 146 reported PI3KCA, but also AKT1 germline mutations in some families revealing the Cowden or a Cowden-like syndrome.
Breast cancer patients with oestrogen receptor-positive tumours revealing HER-2 amplification have been shown to respond poorly to endocrine therapy with aromatase inhibitors as well as tamoxifen. 147 Adding trastuzumab 148 or lapatinib 149 in concert improves response to aromatase inhibitors. The finding that mTOR inhibition may reverse resistance to endocrine agents in breast cancer MCF-7 cells 150, 151 is consistent with clinical findings; recently, two studies reported addition of the mTOR inhibitor everolimus to endocrine therapy with the aromatase inhibitor exemestane 152 or the anti-oestrogen tamoxifen, 153 to significantly improve response to therapy in cancers nonamplified for HER-2. Although these findings indicate elevated Akt/mTOR activity as a cause of endocrine resistance in breast cancer, notably mTOR inhibition may have anti-tumour effects in other malignant conditions, including renal cancer, 154 although it works less efficient in other tumour types like endometrial carcinomas. 155 The Akt/mTOR pathway may be activated through cell surface receptors like the insulin-like growth factor 1 receptor and HER-2, but in addition through pathological activation of the PI3K/Akt system. Thus, activating mutations in exons 9 or 20 in the PI3K subunit PIK3CA have been detected in 15-25% of all breast cancers, 156 but are seen more frequently among oestrogen receptor-positive tumours belonging to the luminal A class. 157 In addition, approximately 5% of breast cancers may harbour activating mutations in AKT. 158 The fact that strong immunostaining for Akt has been associated with a poor prognosis in breast cancer patients independent of adjuvant therapy [159] [160] [161] indicates a general prognostic role for activation of the PI3K/Akt system in breast cancer. Notably, experimental evidence has linked activation of the Akt/mTOR pathway to a number of biological processes; overexpressing Akt has been shown to enhance lymphangiogenesis and confer resistance to cyclophosphamide as well as doxorubicin in murine models, 162 effects that are reversed by blocking Akt's downstream effector mTOR by rapamycin. Further, mTOR inhibitors like rapamycin and everolimus have been shown to inhibit growth of triple-negative breast cancer cell lines, reverse doxorubicin resistance and enhance docetaxel effects in vitro. [163] [164] [165] Finally, experimental evidence has linked elevated Akt activity to enhanced p53 degradation, 166 and there is evidence for synergistic interactions between PI3K and poly(ADP-ribose) polymerase (PARP) inhibition, 167 thus linking Akt activity to the p53 pathway as well as homologous end repair.
PTEN has a role in several biological processes. Thus, although much focus has been on its role as a suppressor of PI3K activity, 143 notably, PTEN has also been involved in maintaining chromosomal integrity, 168 and it interacts with the p53 pathway on several levels. Thus, whereas p53 enhances PTEN transcription, PTEN physically stabilizes the p53 protein by direct interaction, in addition to transcriptional downregulation of MDM2 through the P1 promoter and inhibition of Akt-dependent MDM2 phosphorylations. 93, [169] [170] [171] [172] [173] DNA damage, on the other hand, may lead to p53-dependent degradation of Akt. 174 Although somatic mutations in PTEN occurs at high frequency in some cancers, like endometrial carcinomas, they are rare in breast cancer. 175 In contrast, PTEN protein expression is absent in about 40% of all breast cancers. [176] [177] [178] Although PTEN promoter methylation has been reported, 179 an unknown but probably high proportion of these findings relate to cross-reactions with the pseudogene PTENP1. 180 Studying prostatic cancer, Pandolfi and co-workers 181, 182 have shown PTENP1 to be transcribed and have provided evidence indicating it may act as a decoy, competing with the PTEN transcript for miRNA binding. If these findings are confirmed in other cancer forms as well, it may have significant implications to our understanding of PTEN regulation, but probably regulation of other genes as well.
Although the full mechanisms remains to be elucidated, mTOR activity should be clearly explored as a potential mechanism of resistance towards endocrine therapy and, probably, chemotherapy as well.
DNA REPAIR PATHWAYS
For a detailed outline of the different mechanisms of DNA repair, the readers are referred to recent reviews. [183] [184] [185] Here we will discuss contemporary knowledge linking disturbances in DNA repair pathways to therapy sensitivity/resistance and compare this with findings related to cancer risk syndromes.
As for DNA repair, six mechanisms have been identified; these include nucleotide excision repair (NER), base excision repair (BER), homologous recombination repair (HRR), non-homologous end joining (NHEJ), mismatch repair (MMR) and O 6 -methyl-guanine-DNA methyltrasferase (MGMT; Figure 4) . Although the type of DNA lesion preferentially targeted by each mechanism is known, 183 notably, there is evidence for direct interaction between components of the different repair systems as well as between DNA repair and the p53 pathway. [186] [187] [188] [189] [190] [191] [192] [193] [194] Although loss of apoptotic/senescent function in theory should be expected to cause therapy resistance, the opposite may be the case in DNA repair. Drugs like alkylating agents generate 8-oxoguanine and single-strand breaks subject to repair by BER, whereas platinum-containing compounds generate interstrand crosslinks and double-strand breaks. 185 Leaving such serious DNA lesions intact without any repair may subsequently lead to cell death.
NUCLEOTIDE EXCISION REPAIR
NERs include multiple components involved in bulky adduct and intrastrand crosslink repair in response to different damaging agents, including UV light. 185 Germline mutations affecting NER is the cause of the autosomal recessive disorder xeroderma pigmentosum, associated with a profoundly elevated risk of all types of cancers of the skin. 195, 196 Although HRR is considered the major mechanism inactivating platinum-generated adducts, 197 experimental studies have implicated a role for NER as well. 198 Interestingly, experimental but also clinical evidence have linked expression levels of ERCC1, a component of the NER pathway, to lack of sensitivity to platinum compounds in different malignant conditions, including cancers of the ovary, 199 stomach, 200 endometrium 201 and lung, as well as head and neck cancer-derived cell lines. 202, 203 The fact that ERCC1 expression levels correlated to poor survival in lung cancer patients treated with platinum-based chemotherapy 204 indicates an association between ERCC1 expression levels and chemosensitivity, although a prognostic effect not related to therapy may not be excluded. variant associated with lower enzyme activity of the xeroderma pigmentosum group D gene has been linked to higher response rate to combined treatment with 5-fluorouracil and oxaliplatin in colorectal cancer. 205 
BASE EXCISION REPAIR
Although germline mutations in BER genes have not been detected in any cancer risk syndromes, conflicting evidence has linked polymorphisms to risk of melanoma as well as cancers of the breast and bladder (see references in Santonocito et al. 206 ). Experimental evidence has linked expression levels of Pol-b, a key component of the BER pathway, to resistance to oxaliplatin across a panel of different cell lines, 207 but so far we lack data from clinical studies. BER however has an important role with respect to so-called 'synthetic lethality' through PARP inhibition; this topic is discussed below with respect to HRR.
HOMOLOGOUS RECOMBINATION REPAIR
Although the role of BRCA1/2 mutations inferring enhanced risk of breast and ovarian cancer is well documented, 208, 209 germline mutations affecting other genes in the Fanconi complex (see below) like PALB2 (FANCN) and BRIP1 (FANCJ) has been associated with elevated risk for ovarian cancer. 210, 211 In addition, germline mutations in RAD51C and RAD51D, more recently shown to interact with the Fanconi pathway 212 as well as RAD51 and the BRCA1 co-factor BARD, have all been associated with predisposition to breast and/or ovarian cancer. [213] [214] [215] These findings, revealing defects in the Fanconi pathway beyond BRCA1/2 mutations to be associated with cancer risk, advocate disturbances in other Fanconi complex components to be examined with respect to drug sensitivity/resistance as well (see below).
BRCA1 and BRCA2 have a key role in HRR. BRCA2 is part of the Fanconi complex (FANCD1), whereas BRCA1 has a critical role as a downstream executor from the complex (see Valerie et al., 216 and Garcia and Benitez 217 for details). In contrast to BRCA2-mutated tumours that display gene expression profiles resembling spontaneous breast cancers, about 80% of all breast cancers developing in individuals carrying a BRCA1 mutation reveal a gene expression profile resembling the so-called 'basal-like' breast cancers.
Although the term 'triple-negative', (meaning tumours lacking expression of the oestrogen and progesterone receptors, as well as being non-amplified for HER-2) sometimes is used synonymous to 'basal-like' breast cancers, notably only between 60-80% of all triple-negative breast cancers are actually classified as 'basal-like' based on gene expression or protein biomarker profiling. 218, 219 Studies evaluating pre-surgical chemotherapy for primary breast cancers reported a higher complete response rate to anthracycline- [220] [221] [222] and to platinum-containing 223, 224 regimens for triple-negative as compared with other breast cancers. Although about 10% of all basal-like breast cancers have been diagnosed in BRCA1 germline mutation carriers, 225 currently we have limited knowledge whether other components of the Fanconi system are disturbed in triple-negative/basal-like breast cancer.
In contrast to triple-negative breast cancers, the number of patients harbouring BRCA1/2-mutated tumours enrolled in studies evaluating predictive factors is low; thus, current evidence should be interpreted with caution. Conflicting evidence indicate little difference in response to anthracycline-containing chemotherapy for BRCA1/2 mutation carriers as compared with individuals harbouring wild-type BRCA1/2 in primary as well as metastatic breast cancer. [226] [227] [228] Regarding platinum-containing therapy for breast cancer patients with BRCA1/2 mutations, anecdotical evidence indicate a high complete response rate to such regimens in the primary setting. 229, 230 In contrast, BRCA1 mutation carriers have been reported to respond poorly to taxane-based chemotherapy for metastatic breast cancer. 231 Notably, BRCA1 downregulation has been shown to confer taxane resistance in MCF-7 cells owing to premature inactivation of the spindle checkpoint. 232 Although BRCA1/2 germline mutations are rare in breast cancer, they may account for 10-15% of all cases of ovarian cancers (see Alsop et al. 233 with references). Owing to 'debulking surgery', ovarian cancer patients undergoing chemotherapy often have non-measurable disease; thus, progression within 6 months of completing first-line platinum-based chemotherapy has been defined as drug resistance. 234 Several studies have revealed ovarian cancer patients with BRCA1 as well as BRCA2 germline mutations to have a better chance of responding to platinumbased therapy as compared with patients wild type for BRCA1/2 in the primary setting as well as on tumour relapse. 233, [235] [236] [237] [238] Most interestingly, there is experimental (BRCA2) but also results in human tumours (BRCA1 and BRCA2) revealing secondary mutations, restoring BRCA1/2 protein function, to be associated with acquired resistance toward platinum compounds. [239] [240] [241] [242] The fact that mutations affecting both BRCA1 and BRCA2 seem to confer sensitivity to platinum compounds and to PARP inhibitors (see below) clearly implicates the Fanconi complex in drug sensitivity to these compounds. Although little is known with respect to effects of defects in other components of the Fanconi complex on drug sensitivity, interestingly defects in RAD51D has been shown to enhance sensitivity to cisplatin in mouse cells. 243 The concept of 'synthetic lethality' in cancer treatment was proposed by Hartwell et al. in 1997. 244 Eight years later, two groups 245, 246 independently reported killing of BRCA1/2-mutated cells with use of PARP inhibitors. PARP has a critical role to BER and single DNA strand repair; in case of PARP inhibition, such lesions may proceed to double-strand breaks, to be handled by HRR. 247 Thus, ovarian and breast cancer cells harbouring BRCA1/2 mutations that, in most cases are accompanied by loss of the healthy allele, 248 are sensitized to the toxic effect of PARP inhibitors. Several studies have confirmed anti-tumour effects in human breast and ovarian cancers in patients carrying BRCA1 or BRCA2 germline mutations. [249] [250] [251] [252] [253] [254] Of note, although ovarian cancer patients treated for high-grade epithelial cancers not harbouring BRCA1/2 germline mutations responded to PARP inhibition with Olaparib with a response rate similar to that of BRCA1/2 mutation carriers, no response to Olaparib monotherapy was recorded among patients treated for triple-negative breast cancer harbouring wild-type BRCA1/2. 253 BRCA1/2 somatic and germline mutations are observed more frequently in ovarian (420%) as compared with breast cancers; 255 yet, the finding of a high response rate to PARP inhibitors in high-grade ovarian cancers suggests alternative mechanisms of HRR inactivation may operate in addition. Although the ovarian cancer genome atlas reported a low incidence of mutations in other genes involved in the Fanconi complex, 256 there may be other mechanisms involved, including miRNA-mediated downregulation of BRCA1, 257 which has been reported in triple-negative breast cancers. 258 Anecdotically, a remarkable response to mitomycin was observed in a patient with pancreatic cancer harbouring biallelic PALB2 mutations. 259 Although PARP inhibitors administered as monotherapy was found ineffective in triple-negative breast cancer, experimental evidence has indicated synergistic lethality between cisplatin and PARP inhibitors in triple-negative breast cancer cells not harbouring BRCA1/2 mutations. 260 Adding a second PARP inhibitor, Iniparib, to treatment with gemcitabine and carboplatin improved response rates and time to progression in patients with metastatic triple-negative breast cancer in a phase II study; 261 however, a phase III follow-up study failed to confirm significant Mapping genetic alterations causing chemoresistance PE Lønning and S Knappskog improvement. 262 Notably, recent experimental evidence has thrown doubt on the efficacy of Iniparib as a PARP inhibitor. 263 Although PARP may interact with multiple processes involved in DNA damage response 264 and experimental evidence suggested PARP inhibitors may enhance cytotoxic efficacy of different cytotoxic compounds including temozolamide in different models, 265 as for today the jury is still out regarding whether PARP inhibition may have any place in the clinic for tumours wild type for BRCA1/2 except for high-grade ovarian cancers. Immunohistochemical studies have reported reduced 266 as well as elevated 267 PARP expression in triple-negative compared with other types of breast cancers; interestingly, the second study 267 linked elevated PARP levels to improved effect of anthracyclinetaxane combined chemotherapy
NON-HOMOLOGOUS END JOINING
Germline defects in the components of the NHEJ machinery causes syndromes characterized by immunodeficiency (SCID), radiosensitivity and mircocephaly. 268 However, the role for such defects with respect to cancer is unclear. Although SNP profiles in five NHEJ-involved genes have been found to be associated with breast cancer risk, 269 in vitro work in breast cancer cell lines has revealed that even though there is a large number of structural rearrangements in most cancer cell genomes, this phenomenon is not associated with major defects in the NHEJ pathway. 270 A potential role for alterations of NHEJ function in therapy response remains to be elucidated.
MISMATCH REPAIR
Germline mutations in genes involved in MMR are the cause of non-polypomatous cancer of the colon, or the Lynch syndrome. In addition to elevated risk of cancer of the large bowel, the syndrome includes enhanced risk for cancer of the endometrium, ovary and the brain. The genes most frequently mutated are MLH1 and MSH2, and more rarely MSH6 and PMS2. 271 Approximately 15% of all cancers of the large bowel express the so-called 'microsatellite instability' phenotype, 272 strongly associated with defects in the MMR system. 273 Defects in the mismatch system has been related to inferior response to 5-fluorouracil in cancer of the large bowel, 272 but more lately to an inferior response to cisplatin in germ-cell tumours (testicular seminomas and non-seminomas) as well. 274 In contrast, there is experimental evidence indicating enhanced response to methotrexate-induced oxidative damage in MSH2-deficient endometrial and colon cancer-derived cells, 275 but reduced response to thiopurines in leukemia cells. -METHYL-GUANINE-DNA-METHYLTRANSFERASE In addition to the mechanisms described above, MGMT has a role in therapy sensitivity. MGMT acts by removing alkyl groups from the O 6 -position on guanine; 277 thus, similar to base excision repair, it may detoxify the effect of alkylating compounds on tumour cells. Although not being subjected to mutations, MGMT downregulation due to promoter methylation has been shown to predict response to temozolomide, but not to temozolomide in concert with cisplatinum in patients with high-grade gliomas or glioblastomas. 278, 279 The hypothesis that low levels of MGMT predict temozolomide efficacy is further supported by a study revealing improved survival related to MGMT methylation in glioblastoma patients receiving temozolomide therapy, 280 although in this case study design do not allow a distinction between prediction and prognostication (effect of biology independent of specific therapy).
WAY FORWARD
To properly assess the predictive value of potential biomarkers, there is a need for properly designed studies. As described and depicted in Figure 1 , we suggest three different ways of performing such studies: (a) comparison of outcome in patients positive or negative for a biomarker receiving different treatment regimens in the adjuvant setting, (b) comparison of biomarkers in resistant versus sensitive tumours subject to direct assessment and (c) comparison of the fraction of cells harbouring a biomarker in pre-and post-treatment samples.
Massive parallel sequencing and other emerging technologies provide novel opportunities by analyzing multiple genes in concert as well as the possibility of quantifying the percentage of cells within the tumour tissue harbouring a specific mutation. This allows the possibility to determine clonal selection or elimination during therapy (Figure 2) . Although each tumour contains hundreds of different mutations and genetic alterations, it has become generally accepted that a few ones only may act as the so-called 'drivers' in carcinogenesis, contrasting the large amount of 'passengers' generated by genomic instability but contributing little to the tumour phenotype. 281, 282 Substantial evidence now points that chemoresistance, to a large extent, may be due to disturbances in a limited number of 'gene cascades' or 'functional pathways'. This relates, in particular, to gene pathways involved in apoptosis/senescence and DNA repair. As for most of these pathways, they contain proteins coded for by genes involved in inherited cancer syndromes. Thus, these genes may be coined 'beacons' or, perhaps, better 'drivers' by which the road towards drug resistance may be identified. Although some 'kinase pathways' like the akt/mTOR pathway seems to be involved as well, notably, this pathway acts in concert with tumour suppressors involved in DNA damage response as well as proteins coded for by genes involved in inherited cancer risk syndromes (such as PTEN and TP53). 283, 284 Notably, there are cross talks between components of these pathways, and it is likely that different pathways are of variable importance in different tissue compartments. Conceptually, this parallels what we observe for germline mutations and tissue-specific cancer forms. Although germline mutations affect every body compartment, for reasons unexplained, mutations in particular genes leave the individuals prone to cancer in particular organs. A striking example includes CDKN2A coding for p16; whereas germline mutations in this gene are associated with a high risk of melanoma, mutations affecting the RB1 gene, coding for the RB protein acting downstream of p16, are associated with RBs.
Exploring the mechanisms of drug resistance, clearly there is a need to analyze multiple genes in concert. However, while massive parallel sequencing will generate an enormous amount of interesting data from each tumour, identification of the 'drivers' of chemoresistance through analyses of all genes in a high number of tumours, with subsequent statistical assessments, without any clear hypothesis based on biology, seems a nonefficient way forward. Instead, we propose to take advantage of current biological knowledge. Concentrating efforts on DNA damage, apoptosis and DNA repair, and the key 'beacon genes'/ functional pathways involved in these processes, we believe, may lead towards successful programmes assessing the mechanisms of chemoresistance based on a limited number of genes. TIMP-1 is significantly associated with objective response and survival in
